Portfolio and Disease Areas

Nicox’s Innovative Portfolio

Led by NCX 470, a derisked product candidate with global potential

Pre-clinical Phase 1 Phase 2 Phase 3 NDA Marketed
3 Product Candidates
NCX 470 | novel NO-donating bimatoprost eyedrop
NCX 470 | novel NO-donating bimatoprost eyedrop Glaucoma & Ocular Hypertension Licensed to Ocumension for Chinese & SE Asian markets and to KOWA for Japanese market
Mont Blanc Phase 3 trial completed – Denali Phase 3 trial ongoing – Whistler Phase 3b ongoing
NCX 1728 | NO-donating PDE5 inhibitor
NCX 1728 | NO-donating PDE5 inhibitor Retinal Conditions
NCX 4251 | fluticasone propionate nanocrystal suspension
NCX 4251 | fluticasone propionate nanocrystal suspension Dry Eye Disease
Partnered with Ocumension Therapeutics for the Chinese market
2 Revenue Generating Products
VYZULTA®
VYZULTA® Glaucoma
Licenced to Bausch + Lomb: worldwide
ZERVIATE®
ZERVIATE® Allergic Conjunctivitis
Licenced to Harrow: United States
Licenced to Ocumension Therapeutics for the Chinese & Southeast Asian markets

Disease focus areas

Glaucoma

A major cause of blindness
Glaucoma is a disease of the optic nerve which, if left untreated, can lead to irreversible vision loss. It is currently considered to be one of the three leading causes of irreversible blindness worldwide.

Glaucoma

Glaucoma is a disease of the optic nerve which, if left untreated, can lead to irreversible vision loss. It is currently considered to be one of the three leading causes of irreversible blindness worldwide. Glaucoma is frequently linked to elevated intraocular pressure (IOP) and is often due to blockage in the drainage system located in the front of the eye. Currently, reducing intraocular pressure remains the only way to slow the progression of the disease. Glaucoma affects millions of patients worldwide. About 3.5% of the worldwide population between 40 and 80 years are estimated to be affected by the most common form of glaucoma.

Current medications act by reducing IOP to slow the progression of the disease. It is generally accepted that every mmHg of IOP lowering results in a risk reduction disease progression of approximately 10%. Numerous eye drops are available that either decrease the amount of fluid produced in the eye or improve its flow out of the eye. 40% of patients fail to reach target IOP with existing monotherapies, risking disease progression and vision loss. Despite having well established first line therapies, including the standard of care, latanoprost, there remains an unmet need for therapy with a greater IOP-lowering efficacy that is both safe and well tolerated.

Glaucoma affects millions of patients worldwide.

About 3.5%

Sufferers

About 3.5% of the worldwide population between 40 and 80 years are estimated to be affected by the most common form of glaucoma.
50%

Undetected

Open-angle glaucoma, the most common form, often results in increased eye pressure. There are typically no early symptoms, which is why 50% of people with glaucoma don’t know they have the disease.
x2

Diabetes risk

People with diabetes are 2 times more likely to get glaucoma than people without diabetes.

Allergic Conjunctivitis

One of the most common eye conditions
Allergic conjunctivitis occurs when an allergic reaction causes conjunctivitis, an inflammation of the thin layer of tissue that lines the outside of the white surface of the eye and the inner surface of the eyelids.

Allergic Conjunctivitis

Allergic conjunctivitis occurs when an allergic reaction causes conjunctivitis, an inflammation of the thin layer of tissue that lines the outside of the white surface of the eye and the inner surface of the eyelids. It may affect one or both eyes. The signs and symptoms may include eye redness, excessive watering, itchy burning eyes, discharge, blurred vision and increased sensitivity to light. It is estimated that more than 75 million people suffer from allergic conjunctivitis in the United States and the estimated prevalence of allergic conjunctivitis may be between 15% and 40%.

 

Allergic conjunctivitis is common in people who have other signs of allergic disease, such as hay fever, asthma, and eczema. It is caused by the body’s reaction to certain substances it is allergic to.

75m

People suffering

It is estimated that more than 75 million people suffer from allergic conjunctivitis in the United States
40%

Prevalence

Of those in the United States suffering from allergic conjunctivitis, it is estimated prevalence may be between 15% and 40%

Dry eye disease

Dry eye disease is a common condition that occurs when the quality and/or quantity of tears aren’t able to adequately hydrate or lubricate the eyes.

Dry eye disease

Dry eye disease is a common condition that occurs when the quality and/or quantity of tears aren’t able to adequately hydrate or lubricate the eyes.  This inadequate lubrication can lead to dryness, inflammation, pain, discomfort, irritation, diminished quality of life, and in severe cases, permanent vision impairment.

34m

Sufferers

Around 34 million adults are estimated to be suffering from dry eye disease in the U.S. alone

Our portfolio at a glance

Product candidates

NCX 470

Nicox’s lead clinical product candidate
NCX 470, is a novel nitric oxide (NO)-donating bimatoprost eye drop, in Phase 3 clinical development for the lowering of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension.

NCX 470

Mont Blanc Phase 3 trial completed – Second Phase 3 trial, Denali, ongoing in the U.S. and China with Nicox’s Chinese partner and exclusive licensee Ocumension Therapeutics – Whistler Phase 3b ongoing

Exclusively licensed to Kowa for development and commercialisation of NCX 470 in Japan

Looking for commercial partnership for the U.S.

Expected milestones

  • Completion of recruitment of U.S. patients of Denali Phase 3 trial expected in Q4 2024. Topline results of Denali trial expected in H2 2025
  • Results of Whistler Phase 3b trial investigating NCX 470’s dual mechanism of action in IOP lowering expected in Q1 2025

NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. NCX 470 is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small, naturally occurring signaling molecule that plays a key role in the regulation of IOP through activation of soluble guanylate cyclase (sGC). NO brings additional IOP-lowering efficacy by enhancing aqueous humor drainage from the eye via a different mechanism of action to that of PGAs. Bimatoprost, marketed under the brand name LUMIGAN® by AbbVie, Inc., is the leading branded PGA. PGAs are the most widely used class of drugs for IOP-lowering in patients with open-angle glaucoma or ocular hypertension. We believe that the proven dual mechanism of action can achieve superior IOP-lowering compared to the parent compound alone. Beneficial effects of NCX 470 have additionally been demonstrated in an in vivo model of retinal cell damage (see Press Release of September 29, 2021).

Topline results from the first Mont Blanc Phase 3 clinical trial evaluating the IOP lowering efficacy of once-daily dosed NCX 470 ophthalmic solution 0.1% compared to latanoprost ophthalmic solution 0.005% in patients with open-angle glaucoma or ocular hypertension were announced on October 31, 2022. The first of two Phase 3 trials for NCX 470, Mont Blanc, met the efficacy requirements for approval in the U.S. Daily dosing of NCX 470 0.1% met the primary efficacy objective of demonstrating non-inferiority to latanoprost 0.005%, with NCX 470 showing 8.0 to 9.7 mmHg IOP lowering from baseline. NCX 470 0.1% was statistically superior to latanoprost 0.005% in IOP reduction from baseline at 4 of the 6 timepoints, and numerically greater at all 6 timepoints. However, the secondary efficacy objective, statistical superiority to latanoprost, was not achieved. NCX 470 0.1% was well tolerated. Latanoprost, marketed as Xalatan and available as a generic, is the most prescribed PGA in the U.S.

The similarly designed and ongoing second Phase 3 trial, Denali, conducted at clinical sites in the U.S. and China is ongoing.  The completion of recruitment of U.S. patients of Denali Phase 3 trial expected in Q4 2024. Topline results are expected in H2 2025. The Denali trial also includes a long-term safety extension through 12 months.

Mont Blanc and Denali trials have been designed to fulfill the regulatory requirements for safety and efficacy Phase 3 trials to support NDA submissions in the U.S. and China.

Exploratory nonclinical studies in a well-defined model with optic nerve head and retina damage (ET-1-induced ischemia/reperfusion) investigated the NCX 470 effects beyond its IOP lowering properties. The results suggest that NCX 470 improves ocular perfusion and retinal function in damaged eyes compared to vehicle and to Lumigan® and may therefore have protective properties for the retina.

A Phase 3b clinical trial, Whistler, investigating NCX 470’s dual mechanism of action (NO and PGA) in IOP lowering has been initiated in December 2023. The Whistler trial will enroll approximately 20 healthy volunteers with ocular hypertension in a double-masked, placebo-controlled study which will investigate the action of NCX 470 on aqueous humor parameters including trabecular meshwork outflow and episcleral venous pressure. Each subject will participate in the trial for ~8 days. The results of Whistler trial are expected in Q1 2025.

Results from the Dolomites Phase 2 trial for NCX 470 in glaucoma were reported in 2019: (see Press Release of October 2, 2019).

NCX 470 is protected worldwide by composition of matter patents until 2029, with a potential extension of up to 5 years in the U.S. and EU and by formulation patents to 2039 in the U.S., EU, Japan and China as well other territories.

NCX 1728

Lead compound in a new class of NO-donating molecules
NCX 1728 is an NO-donating Phosphodiesterase-5 (PDE5) inhibitor in preclinical research with potential for development in glaucoma, including neuroprotection, and retinal conditions.

NCX 1728

Preclinical evaluation

 

Expected milestones

  • Potential option exercise under research and global licensing option agreement with Glaukos

NCX 1728, an NO-donating Phosphodiesterase-5 (PDE5) inhibitor, is the lead compound of a new class of NO-donating molecules in which the NO-mediated effects are enhanced and prolonged by concomitant PDE5 inhibition in the same molecule. PDE5 inhibition has been previously shown to enhance the efficacy and the duration of NO-mediated effects. This class of molecules has the potential for glaucoma and for retinal conditions and is currently being evaluated under a research and license option agreement with Glaukos.

 

Out-licensed products

NCX 4251

A novel, patented, ophthalmic suspension of fluticasone propionate nanocrystals
NCX 4251, a novel, patented, ophthalmic suspension of fluticasone propionate nanocrystals, is at clinical development stage for dry eye disease

NCX 4251

Exclusively partnered for the Chinese market

Available for partnering outside China

Expected milestones:

NCX 4251 is a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, at clinical stage in dry eye disease. NCX 4251 will be the first topical ophthalmic fluticasone product, a two-week, once-daily treatment leveraging Nicox’s proprietary formulation technology. Fluticasone propionate has an affinity for the glucocorticoid receptor approximately ten times greater than dexamethasone, a corticosteroid commonly used in ophthalmology. NCX 4251 is being developed as a topical treatment with unique mode of administration to the eyelid margins via an applicator, minimizing the potential steroid exposure through the cornea which can lead to damaging side effects such as intraocular pressure (IOP) increase found with current topical steroids.

NCX 4251 has been evaluated in a Phase 2 trial, Danube, and a larger Phase 2b trial, Mississippi, both of which studied patients with blepharitis. In the Mississippi trial, once-daily NCX 4251, fluticasone propionate ophthalmic suspension 0.1% was evaluated, versus placebo in patients with acute exacerbations of blepharitis. The primary outcome measure was the proportion of patients achieving complete cure in all three hallmark signs and symptoms of blepharitis, eyelid redness, eyelid debris and eyelid discomfort, at Day 15, with two secondary outcome measures on signs and symptoms of dry eye. The Mississippi trial did not meet the primary or secondary efficacy endpoints. Following a post hoc analysis of the results and a meeting with the U.S. FDA, the development of NCX 4251 is focused on dry eye disease.

Post hoc results of Mississippi trial showed a statistically and clinically significant reduction in dry eye symptoms versus placebo in patients who scored more highly for a key sign of dry eye disease (fluorescein staining). Statistically significant improvements in a number of dry eye symptoms and improvements in one sign (p=0.0524) were seen. NCX 4251 was found to be safe and well-tolerated over 14 days’ treatment, with no serious adverse events, and all of the adverse events for the NCX 4251 treatment arm were mild. There were no discontinuations in the trial due to an adverse event.

The future development of NCX 4251 in the U.S. will require initial manufacturing scale-up followed by two additional efficacy clinical trials, both evaluating one sign and one symptom of dry eye disease, providing long term safety data, and certain additional clinical and non-clinical data to support an NDA submission in the U.S.

Similar to ZERVIATE, we intend to seek regulatory approval for NCX 4251 using the FDA’s 505(b)(2) regulatory pathway. This enables us to rely, in part, on the FDA’s prior findings of safety and efficacy for fluticasone propionate, or published literature, in support of our NDA.

NCX 4251 is protected worldwide by patents until 2033 and to 2040 by additional patents granted in the EU,Japan and China).

 

VYZULTA®

A prostaglandin analog with one of its metabolites being nitric oxide (NO)
VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension. It is exclusively licensed worldwide to Bausch + Lomb, a leading global eye health company. VYZULTA is commercialized in more than 15 countries, including the U.S. and is also approved in a number of other countries.

VYZULTA®

Commercialized in more than 15 countries, including the U.S.

 

Expected milestones:

  • Recurrent revenue

VYZULTA, exclusively licensed worldwide to Bausch + Lomb, is a prostaglandin analog with one of its metabolites being nitric oxide (NO). VYZULTA is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension in the U.S. At approval, VYZULTA was the first eye drop approved in the past 20 years with a novel approach to reduce IOP.

VYZULTA is commercialized in more than 15 countries, including the U.S. where it is covered by a composition of matter patent to 2029.

For further details on VYZULTA, please visit our partner’s dedicated website www.vyzulta.com.

ZERVIATE®

Indicated for the treatment of ocular itching associated with allergic conjunctivitis

ZERVIATE® (cetirizine ophthalmic solution), 0.24%, indicated for the treatment of ocular itching associated with allergic conjunctivitis, is commercialized in the U.S. by U.S. partner Harrow. ZERVIATE has been also exclusively licensed to Ocumension Therapeutics for development and commercialization in the Chinese and the majority of the South East Asian markets. Ocumension received approval of the ZERVIATE New Drug Application in China in September 2024.

ZERVIATE®

Commercialized in U.S. by U.S. partner Harrow

New Drug Application approved in September 2024 in China

Licensed to partners across China, Southeast Asia and the Middle East

Expected milestones:

  • Forthcoming launch in China

ZERVIATE is a novel, patented eye drop formulation of cetirizine approved in the U.S. for ocular itching associated with allergic conjunctivitis.

ZERVIATE is commercialized in the U.S. by exclusive U.S. partner Harrow, Inc., . Approval of the New Drug Application (NDA) to commercialize ZERVIATE in China for ocular itching associated with allergic conjunctivitis was received by our partner, Ocumension, in September 2024.

The ZERVIATE formulation is protected by granted patents in the U.S. to 2030 and 2032, and in Europe, Japan and Canada to 2030.

For further details on ZERVIATE in the U.S., please visit our partner’s dedicated website www.zerviate.com.

Watch how our science works

Nitric oxide donation

The Nicox expertise

We have developed a leading position in the therapeutic application of nitric oxide (NO)-donating compounds in ophthalmology using our proprietary expertise in generating novel, patentable molecules that release NO, creating a significant patent portfolio.

Our NO-donating research platform produced NO-donating compounds targeting glaucoma, including VYZULTA®, our first FDA-approved product, commercialized in the United States and other countries by our exclusive global licensee, Bausch + Lomb, and NCX 470, currently in Phase 3 clinical development.

Nitric oxide donation

The Nicox expertise

We have focused our research efforts on ocular disorders in which NO is believed to play a role, including lowering intraocular pressure (IOP) in glaucoma or in retinal health.

NO is a well-known, small, naturally occurring signaling molecule known to stimulate an intracellular enzyme, soluble guanylate cyclase (sGC), which converts guanosine triphosphate to the second messenger, cyclic guanosine monophosphate (cGMP). NO/sGC signaling pathway plays a key role in the regulation of IOP homeostasis and ocular blood flow. The NO stimulated increase in cGMP in the trabecular meshwork leads to the reduction of intracellular calcium, relaxation of the trabecular meshwork and, consequently, an increase in the outflow of the aqueous humor from the anterior segment of the eye through the primary or conventional outflow pathway. All of the foregoing events are thought to lead to lowering of IOP and enhance ocular perfusion. The effect of NO on IOP may be further increased and/or prolonged by phosphodiasterase type-5 (PDE5) inhibitors, which inhibit the degradation of cGMP.

We have applied key learnings from our research activities to NO-donating moieties attached to other non-PGA therapeutic classes of compounds with the goal of enhancing the NO-mediated effects. This novel class of molecules has the potential for development in retinal conditions and a candidate in this series is under preclinical development for retinopathies and other back-of-eye diseases.

Publications

NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm’s Canal Constructs

Read more

A Randomized, Controlled Comparison of NCX 470, a Nitric Oxide-Donating Bimatoprost, and Latanoprost in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The MONT BLANC Study

Read more

Intraocular Pressure Reduction with NCX 470 versus Latanoprost In Previously Treated Versus Treatment-Naïve Patients

Read more

Intraocular Pressure Reduction with NCX 470 versus Latanoprost Across the Spectrum of Baseline Intraocular Pressures

Read more

NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm’s Canal Constructs

Read more

NCX 470 Exerts Retinal Cell Protection and Enhances Ophthalmic Artery Blood Flow After Ischemia/Reperfusion Injury of Optic Nerve Head and Retina

Read more

NCX 470, a Nitric Oxide Donating Bimatoprost versus Latanoprost Has Greater Proportion of Subjects Achieving ≥10 mmHg IOP Decrease in Phase 3 Trial

Read more

NCX 470, a Nitric Oxide Donating Bimatoprost Compared with Latanoprost – Adaptive Design Period Results from the Phase 3 Mont Blanc Clinical Trial

Read more

Effects of NCX 470, a nitric oxide (NO)-donating bimatoprost, in an in vitro 3D-human trabecular meshwork (TM)/Schlemm’s canal (SC) tissue model

Read more

NCX 470, a nitric oxide (NO)-donating bimatoprost, preserves rabbit eyes from biochemical and functional changes associated with endothelin-1 (ET-1)-induced ischemia/reperfusion injury of optic nerve head and retina

Read more

NCX 470, a Nitric Oxide Donating Bimatoprost, Demonstrates Non-inferiority to Latanoprost in Phase 3 Mont Blanc Clinical Trial

Read more

NCX 470 Restores Ocular Hemodynamics and Retinal Cell Physiology After ET-1-Induced Ischemia/Reperfusion Injury of Optic Nerve and Retina in Rabbits

Read more

NCX 470, a nitric oxide (NO)-donating prostaglandin analog, restores ocular hemodynamics and photoreceptor function after endothelin-1-induced ischemia/reperfusion injury in rabbits

Read more

NCX 470, a nitric oxide (NO)-donating prostaglanding analog, elicits sustained IOP-lowering and modifies aqueous humor dynamic in non-human primates

Read more

A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042% and 0.065%) and Latanoprost 0.005% in Patients with Open-Angle Glaucoma or Ocular Hypertension: The Dolomites Study

Read more

Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma Francesco Impagnatiello; Elena Bastia; Nicoletta Almirante; Stefania Brambilla; Brigitte Duquesroix; Angela C Kothe; Michael V W Bergamini

Read more

NCX 470, a nitric oxide (NO)-donating bimatoprost lowers intraocular pressure in rabbits, dogs and non-human primate models of glaucoma Francesco Impagnatiello; Elena Bastia; Carol B Toris; Achim H Krauss; Ganesh Prasanna; Ennio Ongini Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5809. doi

Read more

Intraocular pressure-lowering activity of NCX 470, a novel nitric oxide-donating bimatoprost in preclinical models. Impagnatiello F, Toris CB, Batugo M, Prasanna G, Borghi V, Bastia E, Ongini E, Krauss AH. Invest Ophthalmol Vis Sci. 2015;56(11):6558-64. http://iovs.arvojournals.org/article.aspx?articleid=2461805

Read more

Eyelid Application of NCX 4251 for Treatment of Signs and Symptoms of Dry Eye Disease

Read more

Nonclinical Evaluation of NCX 4251, a Novel Steroid Therapy for Blepharitis, Targeted Directly to the Eyelid Margin to Improve Efficacy and Reduce the Potential for IOP Elevations Robert Fechtner, MD; Tomas Navratil, PhD; Jean-Michel Bukowski, PhD; Frederic Pilotaz, PharmD; Amanda Graves; Akshay Nadkarni; Brigitte Duquesroix, MD; Angela Kothe, PhD, OD; Michael Bergamini, PhD; Harvey DuBiner, MD; Thomas Walters, MD; Donald Budenz, MD

Read more

Latanoprostene Bunod 0.024% in Patients with Open-Angle Glaucoma Switched from Prior Pharmacotherapy: A Retrospective Chart Review. Constance O Okeke, Nora Lee Cothran, Desirae A Brinkley, Kamran Rahmatnejad,Frank J Rodiño, James E Deom

Read more

Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings Robert N. Weinreb, Jeffrey M. Liebmann, Keith R. Martin, Paul L. Kaufman,Jason L. Vittitow

Read more

Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension The APOLLO Study. Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Ophthalmol. 2016;123:965-73.

Read more

Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: The LUNAR Study. Medeiros FA, Martin KR, Peace J, Scassellati Sforzolini B, Vittitow JL, Weinreb RN. Am J Ophthalmol. 2016;168:250–9.

Read more

Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study Kazuhide Kawase, Jason L. Vittitow, Robert N. Weinreb, Makoto Araie For the JUPITER Study Group

Read more

Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours JOHN H.K. LIU, JOHN R. SLIGHT, JASON L. VITTITOW, BALDO SCASSELLATI SFORZOLINI, ROBERT N. WEINREB

Read more

Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24h in Healthy Japanese Subjects Makoto Araie, Baldo Scassellati Sforzolini, Jason Vittitow, Robert N. Weinreb

Read more

A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Weinreb RN, Ong T, Scassellati Sforzolini B, Vittitow JL, Singh K, Kaufman PL; VOYAGER study group. Br J Ophthalmol. 2015;99(6):738-45.

Read more

Regulation of endothelin-1-induced trabecular meshwork cell contractility by latanoprostene bunod. Cavet ME, Vollmer TR, Harrington KL, VanDerMeid K, Richardson ME. Invest Ophthalmol Vis Sci. 2015;56(6):4108-16. http://iovs.arvojournals.org/article.aspx?articleid=2363039

Read more

Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. Krauss AH, Impagnatiello F, Toris CB, Gale DC, Prasanna G, Borghi V, Chiroli V, Chong WK, Carreiro ST, Ongini E. Exp Eye Res. 2011;93(3):250-5.

Read more

NCX 1728, a nitric oxide (NO)-donating PDE-5 inhibitor, but not its des-nitro derivative (NCX 1880), enhances ocular perfusion and improves photoreceptor function in rabbits with endothelin-1 (ET-1)-induced ischemia/reperfusion injury of optic nerve head and retina

Read more

NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys Elena Bastia 1, Carol Toris 2, Jean-Michel Bukowski 3, Stefania Brambilla 1, Corinna Galli 1, Nicoletta Almirante 1, Michael V W Bergamini 4, Laura Lucarini 5, Tomas Navratil 6, Francesco Impagnatiello 1

Read more

NCX 1741, a novel NO-donating derivative of the phosphodiesterase-5 inhibitor avanafil, reduces IOP in models of ocular hypertension and glaucoma Impagnatiello F., Bastia E., Toris C., Fan S., Brambilla S., Galli C., Almirante N., Bergamini M.V.W.

Read more

Intraocular pressure (IOP) reduction elicited with NCX 1741, a dual acting nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitor or travoprost in a non-human primate model of ocular hypertension and glaucoma Impagnatiello F., Navratil T., Toris C.B., Bergamini M.V.W., et al.

Read more

NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances TGFβ2-Induced Outflow in HTM/HSC Constructs Elena Bastia,Carol B.Toris, Stefania Brambilla,Corinna Galli, Nicoletta Almirante,Michael V. W. Bergamini, Emanuela Masini, Silvia Sgambellone, Andrea M. Unser, Feryan Ahmed, Karen Y. Torrejon, Tomas Navratil, and Francesco Impagnatiello

Read more

NCX 667, a novel nitric oxide (NO) donor lowers intraocular pressure (IOP) via stimulation of trabecular meshwork/Schlemm’s canal outflow facility Impagnatiello F, Bastia E, Torrejon KY, Unser AM, Ahmed F. ARVO 2018, Honolulu, Hawaii, USA

Read more

Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma. Bastia E, Impagnatiello F, Ongini E, Serle JB, Bergamini MVW. Invest Ophthalmol Vis Sci. 2017;58(8):2106. ARVO 2017, Baltimore, Maryland, USA

Read more

IOP-lowering effects of NCX 667 in combination with travoprost in ocular normotensive and transient hypertensive rabbits. Bastia E, Masini E, Durante M, Bergamini MVW., Ongini E, Impagnatiello F. Invest Ophthalmol Vis Sci. 2016;57(12):3031. ARVO 2016, Seattle, Washington, USA

Read more

NCX 667, a novel nitric oxide (NO) donor, lowers intraocular pressure (IOP) in ocular normotensive and hypertensive eyes of rabbits and non-human primates. Bastia E, Impagnatiello F, Almirante N, Lanzi C, Masini E, Toris C, Ongini E. Invest Ophthalmol Vis Sci. 2015;56(7):1999. ARVO 2015, Denver, Colorado, USA

Read more

Nitric oxide (NO): an emerging target for glaucoma. Cavet ME, Vittitow JL, Impagnatiello F, Ongini E, Bastia E. Invest Ophthalmol Vis Sci. 2014;55(8):5005-15.

Read more

Cookies

By continuing to use this website, you agree to our Cookie Policy.